Artificial tears: Promising treatment or silent threat to public health?

BACKGROUND AND AIMS: Dry Eye Disease (DED) is a multifactorial chronic inflammatory condition of the corneal surface, attributed to insufficient or low‐quality production of tears, accounting for 5‐50% of the cases globally. Artificial tears are the first line of treatment as they reduce ocular surface tension, and improve film stability and optical quality. EzriCare Artificial Tears are preservative‐free, multi‐dose, readily accessible eye drops containing carboxymethylcellulose sodium solution (10 mg in 1 ml) aiming for relief against DED. This article discusses the public health challenges faced by the use of EzriCare Artificial Tears and emphasizes the need for alternative therapies for the effective management of DED. METHODS: We searched for articles documenting the incidence of the current multi‐drug resistant P. aeruginosa strain outbreak caused by the use of preservative‐free artificial tears and the challenges faced through the use of artificial tears on PubMed, and Google Scholar. RESULTS: EzriCare and other preservative‐free artificial tears have been reported to pose a serious public health risk as they have been found to be the commonly used product among the people infected with the current multi‐state outbreak of the multi‐drug resistant P. aeruginosa strain. CONCLUSION: The current multi‐state outbreak of the multi‐drug resistant P. aeruginosa strain has raised concerns about the safe use of other artificial products. It is high time that further trials should be conducted on other alternative strategies and evaluate the safety and efficacy of nanotechnology in the treatment of dry eye disease.